Oncology
Immuno Oncology
Anti-Virus
Disease Modeling
Cosmetics
Toxicity
Spatial Biology
Technology Service
Cancer Organoid
Research Service
Others
Organism | Human |
Product Type | Organoid + T cell + Regulatory T cell |
Tissue | Adaptive |
Disease |
Applications
Colorectal cancer
Colorectal cancer organoids faithfully mimic patient tumors, aiding drug testing and personalized treatment strategies through biomarker identification and high-throughput screening in a realistic tumor microenvironment
Non-small cell lung cancer
Non-small cell lung cancer organoids mirror patient tumor diversity and genetics, providing a robust platform for detailed cancer research, including drug responses and personalized treatment exploration
Pancreatic cancer
Pancreatic cancer organoids replicate patient tumor complexity, informing drug responses, disease modeling, and biomarker discovery to advance personalized treatment strategies and research
Breast cancer
Patient-derived breast cancer organoids mimic tumor complexities, facilitating diverse drug testing and precision medicine research for personalized treatment strategies
Cholangiocarcinoma
Cholangiocarcinoma organoids aid in personalized treatment strategies by replicating patient tumor complexity and advancing research through biomarker identification and drug screening
A drug evaluation solution co-culturing Treg, T cells, and cancer organoids allows for the assessment of drugs that can regulate Treg. This provides a drug evaluation solution capable of evaluating drugs that can modulate Treg.
We aimed to develop tumor organoids with a tumor microenvironment and use them as a solution for drug evaluation.
For this, we created a system where tumor organoids, cytotoxic T cells, and regulatory T cells were co-cultured at specific ratios.
We activated T cells from PBMCs, then separately cultured and counted cytotoxic T cells and regulatory T cells.
Finally, after establishing the co-culture system at designated ratios, we measured the efficacy of immuno-oncology drugs.
R1 / T-cell
R1 / T-cell
H&E | CK7 | |
|---|---|---|
CD8+ | 47,600 | – |
All Events / Treg
CD4+CD5+ / Treg
H&E | CK7 | |
|---|---|---|
CD8+CD25+FoxP3 | 7,500 | – |
We compared the commonly used immuno-oncology drug atezolizumab with candidate.
When T cells alone or cytotoxic T cells and regulatory T cells were added, we examined the effect of each immuno-oncology drug.
Only in the case of co-culture with regulatory T cells, the efficacy of the drug decreased rapidly.
This is a result of regulatory T cells inducing T cell suppression during co-culture.
These results prove that our solution can most similarly simulate the tumor microenvironment consisting of tumor organoids, cytotoxic T cells and regulatory T cells.
Screen and accurately evaluate anti-cancer drugs targeting regulatory T cells using our validated solution that closely resembles the in vivo tumor microenvironment.
@ 2024 . All rights reserved
@ 2024 . All rights reserved
